[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:hpv16":3},{"name":4,"total":5,"recruiting":6,"trials":7},"HPV16",7,6,[8,16,23,30,36,42,48],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04131413","HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia",[12],"Phase 1","RECRUITING","2026-08-26T02:18:57.189473Z","2026-05-05T02:43:29.166339Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04988074","Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w\u002FHPV H&N Ca",[20],"Phase 2","2026-08-26T02:18:44.395098Z","2026-05-05T02:43:28.875169Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT04534205","A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1",[27],"Phase 2\u002FPhase 3","2026-08-26T02:17:51.502023Z","2026-05-05T02:43:28.001380Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT03913117","Study of Treatment for HPV16+ ASC-US or LSIL",[12],"2026-08-26T02:17:16.126291Z","2026-05-05T02:43:27.995278Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07454915","PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia",[20],"2026-08-26T02:15:13.282904Z","2026-05-05T02:43:27.491389Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT04852328","Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma",[20],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:26.932385Z",{"nct_id":49,"title":50,"phases":51,"status":53,"updated_at":54,"content_modified":55},"NCT07536282","Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection",[52],"Phase 1\u002FPhase 2","NOT_YET_RECRUITING","2026-08-26T02:18:20.384845Z","2026-05-05T02:43:29.678943Z"]